Central nervous system regulation of intestinal lipoprotein metabolism by glucagon-like peptide-1 via a Brain-Gut Axis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 5, 2015, Pages 1092-1100

  Farr, Sarah ^a,b   Baker, Christopher ^b   Naples, Mark ^b   Taher, Jennifer ^a,b   Iqbal, Jahangir ^c   Hussain, Mahmood ^c   Adeli, Khosrow ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c Downstate Health Sciences University   (United States)

Author keywords

apolipoprotein B 48; central nervous system; chylomicron; glucagon like peptide 1

Indexed keywords

ADRENERGIC RECEPTOR; APOLIPOPROTEIN B48; BETA INTERMEDIN[11-22][11 (N ACETYLCYSTEINE) 14 [3 (2 NAPHTHYL) DEXTRO ALANINE] 18 CYSTEINE 22 ASPARTIC ACID AMIDE] 11,18 CYCLIC DISULFIDE; CHYLOMICRON; EXENDIN 4; EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HORMONE ANTAGONIST; INSULIN; MELANOCORTIN 4 RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MK 0626; PHENTOLAMINE; PROPRANOLOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIPOPROTEIN; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE INNERVATION; JEJUNUM; LIPOPROTEIN METABOLISM; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR UPREGULATION; SYRIAN HAMSTER; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; HAMSTER; INNERVATION; INTESTINE; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CHYLOMICRONS; CRICETINAE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; INTESTINES; LIPID METABOLISM; LIPOPROTEINS; PEPTIDES; RANDOM ALLOCATION; RECEPTORS, GLUCAGON; VENOMS;

EID: 84933046243     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304873     Document Type: Article

References (37)

1. Curtin A, Deegan P, Owens D, Collins P, Johnson A, Tomkin GH, Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol 1996 33 205 210
2. Yu KC, Mamo JC, Chylomicron-remnant-induced foam cell formation and cytotoxicity: a possible mechanism of cell death in atherosclerosis. Clin Sci (Lond) 2000 98 183 192
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 339 229 234. doi: 10.1056/NEJM199807233390404
4. Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, Yan P, Smith U, Yki-Järvinen H, Diamant M, Taskinen MR, One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 2010 212 223 229. doi: 10.1016/j.atherosclerosis.2010.04.024
5. Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH, Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-Arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008 30 858 867. doi: 10.1016/j.clinthera.2008.05.004
6. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD, Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010 212 217 222. doi: 10.1016/j.atherosclerosis.2010.05.028
7. Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF, Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 2012 32 1513 1519. doi: 10.1161/ATVBAHA.112.246207
8. Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA, Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006 49 452 458. doi: 10.1007/s00125-005-0126-y
9. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, D'Alessio DA, Tso P, GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005 288 G943 G949. doi: 10.1152/ajpgi.00303.2004
10. Hsieh J, Longuet C, Baker CL, Qin B, Federico LM, Drucker DJ, Adeli K, The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010 53 552 561. doi: 10.1007/s00125-009-1611-5
11. Yoder SM, Yang Q, Kindel TL, Tso P, Stimulation of incretin secretion by dietary lipid: Is it dose dependent? Am J Physiol-Gastr L 2009 297 299 305
12. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001 50 609 613
13. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C, Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997 77 257 270
14. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK, Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002 110 43 52. doi: 10.1172/JCI15595
15. Nogueiras R, Pérez-Tilve D, Veyrat-Durebex C, Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009 29 5916 5925. doi: 10.1523/JNEUROSCI.5977-08.2009
16. Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA, Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol 2009 587 Pt 19 4749 4759. doi: 10.1113/jphysiol.2009.175067
17. Sohn JW, Harris LE, Berglund ED, Liu T, Vong L, Lowell BB, Balthasar N, Williams KW, Elmquist JK, Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons. Cell 2013 152 612 619. doi: 10.1016/j.cell.2012.12.022
18. Dalvi PS, Nazarians-Armavil A, Purser MJ, Belsham DD, Glucagon-like peptide-1 receptor agonist, exendin-4, regulates feeding-Associated neuropeptides in hypothalamic neurons in vivo and in vitro. Endocrinology 2012 153 2208 2222. doi: 10.1210/en.2011-1795
19. Hein GJ, Baker C, Hsieh J, Farr S, Adeli K, GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 2013 62 373 381. doi: 10.2337/db12-0202
20. Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR, Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006 49 2049 2057. doi: 10.1007/s00125-006-0340-2
21. Cabou C, Burcelin R, GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011 8 418 431. doi: 10.1900/RDS.2011.8.418
22. Hisadome K, Reimann F, Gribble FM, Trapp S, CCK stimulation of GLP-1 neurons involves α1-Adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes 2011 60 2701 2709. doi: 10.2337/db11-0489
23. Alvarez E, Martínez MD, Roncero I, Chowen JA, García-Cuartero B, Gispert JD, Sanz C, Vázquez P, Maldonado A, de Cáceres J, Desco M, Pozo MA, Blázquez E, The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005 92 798 806. doi: 10.1111/j.1471-4159.2004.02914.x
24. Merchenthaler I, Lane M, Shughrue P, Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999 403 261 280
25. Sandoval D, CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav 2008 94 670 674. doi: 10.1016/j.physbeh.2008.04.018
26. Perez-Martinez P, Garcia-Rios A, Delgado-Lista J, Delgado-Casado N, Malagon MM, Marin C, Gomez-Luna P, Caballero J, Perez-Jimenez F, Lopez-Miranda J, A variant near the melanocortin-4 receptor gene regulates postprandial lipid metabolism in a healthy Caucasian population. Br J Nutr 2011 106 468 471. doi: 10.1017/S0007114511002212
27. Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL, Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology 2012 153 564 573. doi: 10.1210/en.2011-1732
28. Walley AJ, Asher JE, Froguel P, The genetic contribution to non-syndromic human obesity. Nat Rev Genet 2009 10 431 442. doi: 10.1038/nrg2594
29. Strack AM, Sawyer WB, Hughes JH, Platt KB, Loewy AD, A general pattern of CNS innervation of the sympathetic outflow demonstrated by transneuronal pseudorabies viral infections. Brain Res 1989 491 156 162
30. Iwasa M, Kawabe K, Sapru HN, Activation of melanocortin receptors in the intermediolateral cell column of the upper thoracic cord elicits tachycardia in the rat. Am J Physiol Heart Circ Physiol 2013 305 H885 H893. doi: 10.1152/ajpheart.00443.2013
31. Boehnke J, Sweep FC, Dobberstein K, Strauss A, Engeli S, Luft FC, Budziarek P, Jordan J, Boschmann M, Foley JE, He Y, Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocr Metab 2009 94 846 852
32. Giralt M, Vergara P, Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat. Regul Pept 1998 74 19 25
33. Baglole CJ, Davison JS, Meddings JB, Epithelial distribution of neural receptors in the guinea pig small intestine. Can J Physiol Pharmacol 2005 83 389 395. doi: 10.1139/y05-024
34. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S, Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-Activated protein kinase. J Hepatol 2011 54 1214 1223. doi: 10.1016/j.jhep.2010.09.032
35. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, Streutker C, Holland D, Cao X, Baggio LL, Drucker DJ, GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013 154 127 139. doi: 10.1210/en.2012-1937
36. Wøjdemann M, Wettergren A, Sternby B, Holst JJ, Larsen S, Rehfeld JF, Olsen O, Inhibition of human gastric lipase secretion by glucagon-like peptide-1. Dig Dis Sci 1998 43 799 805
37. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ, Truncated GLP-1 (proglucagon 78-107-Amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993 38 665 673